Identification of leishmania fructose-1,6-bisphosphate aldolase as a novel activator of host macrophage Src homology 2 domain containing protein tyrosine phosphatase SHP-1

被引:33
作者
Nandan, Devki
Tran, Thao
Trinh, Eva
Silverman, Judith M.
Lopez, Martin
机构
[1] Dept Med, Div Infect Dis, Vancouver, BC V5Z 3J5, Canada
[2] Univ British Columbia, Fac Med & Sci, VCHRI, Vancouver, BC V5Z 3J5, Canada
基金
加拿大健康研究院;
关键词
leishmania; aldolase; protein phosphatase; SHP-1; activator; macrophage;
D O I
10.1016/j.bbrc.2007.10.065
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The macrophage protein tyrosine phosphatase-1 SHP-1 has been implicated in the pathogenesis of infection with leishmania. To identify the factors that may interact with SHP-1, Leishmania donovani promastigote lysates were added to a GST-SHP-1 affinity matrix. A 44 kDa specifically bound protein was identified as leishmania fructose-1,6-bisphosphate aldolase (aldolase). Purified leishmania aldolase bound to SHP-1 indicating that the interaction was direct. In contrast, purified mammalian aldolase did not bind to SHP-1. Consistent with this, leishmania aldolase activated SHP-1 in vitro, whereas mammalian aldolase did not. The presence of leishmania aldolase in the cytosolic fractions prepared from infected macrophages indicated that leishmania aldolase is exported from phagolysosomes in infected cells where it can target host cytosolic proteins. In fact, co-immunoprecipitation showed association of leishmania aldolase with SHP-1. Moreover, leishmania aldolase-expressing macrophages showed the deactivated phenotype of leishmania infected cells as judged by much reduced inability to induce expression of nitric-oxide synthase in response to interferon-gamma treatment. Collectively, these data show that leishmania aldolase is a novel SHP-1 binding and activating protein that contributes to macrophage dysfunction. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:601 / 607
页数:7
相关论文
共 27 条
  • [1] Hijacking the cell: Parasites in the driver's seat
    Beverley, SM
    [J]. CELL, 1996, 87 (05) : 787 - 789
  • [2] Blanchette J, 1999, EUR J IMMUNOL, V29, P3737, DOI 10.1002/(SICI)1521-4141(199911)29:11&lt
  • [3] 3737::AID-IMMU3737&gt
  • [4] 3.0.CO
  • [5] 2-S
  • [6] Early signaling via inhibitory and activating NK receptors
    Bléry, M
    Olcese, L
    Vivier, E
    [J]. HUMAN IMMUNOLOGY, 2000, 61 (01) : 51 - 64
  • [7] Forget G, 2001, EUR J IMMUNOL, V31, P3185, DOI 10.1002/1521-4141(200111)31:11&lt
  • [8] 3185::AID-IMMU3185&gt
  • [9] 3.0.CO
  • [10] 2-J